Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment

Neurology. 2014 Mar 18;82(11):1008-9. doi: 10.1212/WNL.0000000000000218. Epub 2014 Feb 12.

Authors

Linda Rolf¹, Anne-Hilde Muris, Jan Damoiseaux, Marc van Daele, Raymond Hupperts

Affiliation

¹ From the School for Mental Health and Neuroscience (L.R., A.-H.M., R.H.) and the Central Diagnostic Laboratory (J.D.), Maastricht University Medical Center; and Academic MS Center Limburg (L.R., A.-H.M., R.H.) and the Department of Cardiology, Orbis Medical Center (M.v.D.), Sittard, the Netherlands.

PMID: 24523479
DOI: 10.1212/WNL.0000000000000218

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Atrial Fibrillation / chemically induced*
Fingolimod Hydrochloride
Humans
Immunosuppressive Agents / adverse effects*
Male
Multiple Sclerosis / drug therapy
Propylene Glycols / adverse effects*
Sphingosine / adverse effects
Sphingosine / analogs & derivatives*

Substances

Immunosuppressive Agents
Propylene Glycols
Fingolimod Hydrochloride
Sphingosine